The Signal Amidst the Noise

Din Brands: A Value Trap or Hidden Gem? Their Stock has re-emerged in my Filters as a Strong Buy! Sector Consumer Cyclicals Industry Hotels & Entertainment Services Dine Brands Global, Inc., together with its subsidiaries, owns and franchises the Applebee’s Neighborhood Grill + Bar (Applebee’s) concept in the American full-serve restaurant segment within the casual dining category of the restaurant industry. The Company also owns and franchises the International House of Pancakes (IHOP) concept in the midscale full-service restaurant segment within the family dining category of the restaurant industry and Fuzzy’s Taco Shop (Fuzzy’s) concept in the Mexican limited-service restaurant segment. Its segments include franchise operations, Rental operations, Financing operations and Company restaurant operations. The franchise operations segment consists of approximately 1,567 Applebee’s franchised restaurants; 1,824 IHOP franchised and area licensed restaurants, and 116 Fuzzy's franc...

It's that time again – Earnings Season! The air is thick with anticipation, and today's docket is overflowing with reports. While many companies are vying for attention, one, in particular, has caught my eye: Tesla (TSLA) . My wife an I recently became happy owners of Model 3! The electric vehicle giant has seen a notable decline, sliding down the S&P 500 rankings to number 11, just a hair ahead of the retail behemoth, Walmart (WMT) . From my vantage point, both of these companies currently sit at what I consider a less-than-ideal entry point, with a significant amount of future optimism already baked into their prices. This kind of scenario, where high expectations meet potential earnings realities, often creates fertile ground for trading. Large financial institutions frequently capitalize on the influx of capital, including those seemingly endless retirement contributions from the average investor. The burning questions, of course, are: where should the profit target...

Personal Commentary: When Yield Feels Like Home I’ll be honest—I regret cashing out some of my Kinder Morgan (KMI) . Hindsight is always smug like that. Sure, the price looked stretched at the time, but I miss those sweet dividend deposits rolling in. I'm still holding a position and reinvesting dividends , because, honestly, the yield still beats my savings account —even at today’s price. Lately, my attention has shifted toward Western Midstream Partners (WES) . The yield is appealing, and the infrastructure is solid, but not everyone agrees with me. Morgan Stanley slapped it with an Underweight rating , and Market Edge tagged it with a “Second Opinion: Avoid.” It’s enough to make you pause. Still, I believe demand for midstream infrastructure isn’t going anywhere. At the same time, I’ve been building a position in Dominion Energy (D) using my dividend capture strategy —I replicate the previous position size plus one share with each round and reinvest the dividends. As the pr...

There's a rising pushback against tariffs in the U.S.—a collective gasp from consumers who have grown fond of low prices and next-day delivery. The sentiment is usually the same: “Tariffs make things more expensive.” To that, my new reply is simple: “Tariffs will make the cost of things go up… if they're made in a third world country.” And that's the point... Tariffs are often misunderstood as a tool of nationalism or as a blunt instrument in economic warfare. But there's a deeper, more principled foundation to support them: tariffs are a modern rejection of exploitative labor. You could say, in today’s terms, they’re a reversion of slavery cloaked in economics. Cheap goods often come from regions where labor and treatment standards are minimal , and workers are disposable. We tell ourselves it’s progress because it's not happening here—but it’s not really progress. It’s outsourcing suffering and poor treatment of others . Consider the article published by Y...

For investors seeking stable, interest-generating vehicles, the newly issued certificate of deposit (CD) from Jonesboro State Bank in Jonesboro, Louisiana presents a compelling option. Offering a fixed 5.00% annual yield paid monthly , this CD provides a regular income stream and comes with FDIC protection for added security. Key Features: Issuer: Jonesboro State Bank (FDIC #9325) CUSIP: 48040PRB3 Coupon Rate: 5.00% annually (Fixed, Monthly Payouts) Maturity Date: April 18, 2035 Next Call Date: July 18, 2025 (callable at par with 15 days' notice) Minimum Denomination: $1,000 Availability: Restricted in Louisiana Strengths Attractive Yield: In a market where high-yield opportunities are increasingly rare, a 5.00% CD with monthly interest payments stands out. It may appeal to conservative investors seeking predictable income without market volatility. Monthly Payouts: Unlike many CDs that pay quarterly or semiannually, this one distributes ...

Stellus Capital Investment Corp. ( NYSE: SCM ) is quietly positioning itself as a compelling pick for income-focused investors—particularly those of us who appreciate monthly payouts and reliable cash flow. On April 8, the stock surged 3.29%, marking its largest single-day gain since May 2023 , and snapping an eight-day losing streak. While some investors may have been rattled by recent declines, this rebound could be a sign of stability returning. Let’s dig deeper into what makes SCM a standout among dividend-paying stocks—and why I’m bullish on its long-term role in a well-balanced, income-focused portfolio.  Business Model: How SCM Makes Money SCM is a Business Development Company (BDC) , meaning it exists to invest in and lend money to private, middle-market businesses across the United States. In return, SCM earns income through interest on loans, equity stakes, and other structured investments. Here’s how it works: Lending with a twist: SCM provides senior secured ...

Bristol Myers Squibb (BMY), a prominent global biopharmaceutical company, currently trades at a price of $50.68. This analysis aims to determine whether BMY represents a favorable investment opportunity at this valuation by examining its fundamental strengths, technical indicators, and the prevailing macroeconomic environment. This assessment will delve into recent news and analyst sentiment, the company's financial health and drug pipeline, insights from moving averages and Fibonacci retracement levels, and the impact of recent stock market dynamics and the strength of the US dollar. Bristol Myers Squibb: A Snapshot of Fundamentals Recent developments and analyst perspectives provide a mixed view of Bristol Myers Squibb. While the company experienced a setback with the Phase 3 ODYSSEY-HCM trial for Camzyos failing to meet its primary endpoints , which subsequently led to a decrease in the stock price , there have been notable successes. The U.S. Food and Drug Administration (FDA) ...